CSIMarket Company Name, Ticker, Suppliers, else..
 
Editas Medicine Inc   (NASDAQ: EDIT)
Other Ticker:  
 
 
Price: $1.3800 $-0.03 -2.128%
Day's High: $1.48 Week Perf: 13.11 %
Day's Low: $ 1.34 30 Day Perf: 5.34 %
Volume (M): 2,549 52 Wk High: $ 11.58
Volume (M$): $ 3,518 52 Wk Avg: $4.70
Open: $1.41 52 Wk Low: $1.12



 Market Capitalization (Millions $) 114
 Shares Outstanding (Millions) 82
 Employees 143
 Revenues (TTM) (Millions $) 62
 Net Income (TTM) (Millions $) -211
 Cash Flow (TTM) (Millions $) 13
 Capital Exp. (TTM) (Millions $) 10

Editas Medicine Inc
Editas Medicine Inc is a leading biotechnology company that specializes in developing CRISPR gene editing technology for therapeutic purposes. The company aims to improve patients' lives by treating and potentially curing genetic diseases through precise editing of their DNA. Editas Medicine uses its proprietary genome editing platform to address a wide range of genetic diseases, including rare and inherited conditions. The company focuses on developing innovative therapies and partnering with other organizations to bring these treatments to patients. Editas Medicine is at the forefront of the gene editing field and has the potential to revolutionize medicine by providing targeted and personalized treatments.


   Company Address: 11 Hurley Street Cambridge 2141 MA
   Company Phone Number: 401-9000   Stock Exchange / Ticker: NASDAQ EDIT


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
CRBU      % 
DNA      % 
FDMT      % 
IMCR      % 
RGNX      % 
RLAY      % 
• View Complete Report
   



Clinical Study

Breakthrough Data on Reni-cel for Sickle Cell Disease Unveiled at ASH Annual Meeting,

Published Mon, Dec 9 2024 5:00 PM UTC

Updated Insights into Reni-cel Therapy for Severe Sickle Cell Disease Presented at ASH Annual Meeting In a recent development at the 64th American Society of Hematology (ASH) Annual Meeting, Editas Medicine unveiled updated clinical data from its RUBY trial, focusing on the investigational gene-edited therapy, Reni-cel, for patients grappling with severe sickle cell disease....
Management Announcement

Editas Medicine: Balancing the Future of Gene Editing with Strategic Financial Maneuvers Amidst Industry Challenges,

Published Tue, Oct 22 2024 11:00 AM UTC

Editas Medicine: Navigating Financial Challenges while Pioneering Gene Editing SolutionsIn an ever-evolving biotechnology landscape, Editas Medicine Inc. is making strides both in clinical advancements and financial strategy. The company recently announced significant progress towards its 2024 goals, revealing pivotal developments in its quest to treat genetic disorders suc...
Financing Agreement

Editas Medicine: A Strategic Leap in Capitalization and Clinical Achievement

Published Thu, Oct 3 2024 10:01 PM UTC

Balancing Financial Strength Amidst Clinical AdvancementsIn the fast-evolving biotechnology landscape, Editas Medicine Inc. has made a significant move that not only fortifies its balance sheet but also sets the stage for promising pipeline development and strategic priorities. The company?s recent announcement of a non-dilutive capital influx exceeding $50 million from DRI ...
Clinical Study

Editas Medicines Reni-cel Shows Promise in Treating Sickle Cell Disease, Advances in Gene Editing Technology, and Ex...

Published Fri, Jun 14 2024 7:01 AM UTC

In a groundbreaking achievement, Editas Medicine, a leading biotechnology company, presented new safety and efficacy data from the RUBY trial of Reni-cel at the prestigious European Hematology Association (EHA) Annual Congress. The trial included 18 patients with sickle cell disease, and the results have been nothing short of remarkable. All patients treated with Reni-cel re...
Clinical Study

Editas Medicine: Pioneering the Future of Gene Editing for Hematologic Disorders and Beyond

Published Tue, May 14 2024 2:00 PM UTC

Editas Medicine, a leading gene editing company, has recently announced exciting updates in the field of clinical trials. The company is set to present clinical data from the RUBY and EdiTHAL trials of reni-cel at the upcoming European Hematology Association (EHA) Hybrid Congress in Madrid, Spain. The abstracts of these trials have been accepted for both oral and poster pres...






Editas Medicine Inc's Segments





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com